Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine

Psychiatry and Clinical Neurosciences

Volumn 57, Issue 3, 2003, Pages 317-321

  Hsiao, Mei Chun ^a   Liu, Chia Yih ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Premenstrual dysphoric disorder; Serotonin norepinephrine re uptake inhibitor; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ANOREXIA; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INSOMNIA; MENSTRUAL CYCLE; MOOD; NAUSEA; NERVOUSNESS; PREMENSTRUAL DYSPHORIC DISORDER; SELF EVALUATION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AFFECT; CYCLOHEXANOLS; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0038015434     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2003.01123.x     Document Type: Article

References (38)

1. Korzekwa MI, Steiner M. Premenstrual Syndrome. Clin. Obstet. Gynecol. 1997; 40: 564-576.
2. Pearlstein T, Stone AB. Premenstrual Syndromes. Psychiatr. Clin. North Am. 1998; 21: 577-590.
3. Endicott J, Amsterdam J, Eriksson E et al. Is premenstrual dysphoric disorder a distinct clinical entity? J. Womens Ment. Health 1999; 8: 663-679.
4. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study. Obstet. Gynecol. 1992; 80: 339-344.
5. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment of premenstrual dysphoria. N. Engl. J. Med. 1995; 332: 1529-1534.
6. Yorkers KA, Halbreich U, Freeman EW et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial. JAMA 1997; 278: 938-988.
7. Young SA, Hutt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial. J. Clin. Psychiatry 1998; 59: 76-80.
8. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int. Clin. Psychopharmacol. 1999; 14: 527-533.
9. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial. Arch. Gen. Psychiatry 1999; 56: 932-939.
10. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrual syndrome. J. Clin. Psychiatry 2000; 61: 22-27.
11. Morse CA, Dennerstein L, Farrell E et al. A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. J. Behav. Med. 1991; 14: 469-489.
12. Taylor DL, Mathew RJ, Ho BT, Weinman ML. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12: 16-18.
13. Rapkin AJ, Edelmuth E, Chang LC, Reading AE, McGuire MT, Su TP. Whole blood serotonin in premenstrual syndrome. Obstet. Gynecol. 1987; 70: 533-537.
14. Ashby CR, Carr LA, Cook CL, Steptoe MM, Franks DD. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol. Psychiatry 1988; 24: 225-233.
15. Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am. J. Psychiatry 1996; 153: 718-720.
16. Gurguis GN, Yonkers KA, Phan SP, Blakeley JE, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder, I. platelet α2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol. Psychiatry 1998; 44: 600-609.
17. Sundstrom I, Andersson A, Nyberg S, Ashbrook D, Purdy RH, Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67: 126-138.
18. Golden RN, Nicholas L. Antidepressant efficacy of venlafaxine. Depression Anxiety 2000; 12: 45-49.
19. Freeman EW, Rickels K, Yonker KA, Kunz NR, McPherson MK, Upton V. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 2001; 98: 737-744.
20. Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women seeking treatment for premenstrual syndrome in Taiwan. Acta Psychiatr. Scand. 2002; 106: 150-155.
21. Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women utilizing a mental health clinic in a gynecological outpatient setting. Psychiatry Clin. Neurosci. 2002; 56: 459-463.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC, 1994.
23. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998; 59: 22-33.
24. Reid RL. Premenstrual syndrome. Curr. Probl. Obstet. Gynecol. Fertil. 1985; 8: 43-67.
25. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 56-62.
26. Hamilton M. The assessment of anxiety scales by rating. Br. J. Med. Psychol. 1959; 32: 50-55.
27. Raft D, Spencer RF, Toomey T, Brogan D. Validity of the Zung depression scale (SDS) in medical outpatients. Md State Med. J. 1979; 28: 39-41.
28. Spielberger CD, Borsuch RL, Lushene RE. State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, 1970.
29. Silverstone T. New aspects in the treatment of depression. Int. Clin. Psychopharmacol. 1992; 6: 41-44.
30. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J. Affect. Disord. 1998; 47: 55-62.
31. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J. Clin. Psychopharmacol. 1998; 18: 136-144.
32. Freeman EW, Rickels K, Sondheimer SJ, Wittmaack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: An open-label trial. J. Clin. Psychiatry 1996; 57: 7-11.
33. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 1996; 16: 3-8.
34. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J. Clin. Psychiatry 1991; 52: 290-293.
35. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J. Clin. Psychiatry 1997; 58: 399-402.
36. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Arch. Fam. Med. 1999; 8: 328-332.
37. Farah A, Lauer T. Possible venlafaxine withdrawal syndrome. Am. J. Psychiatry 1996; 153: 576.
38. Dallal A, Chouinard G. Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. J. Clin. Psychopharmacol. 1998; 18: 343-344.